Patent ID: 7384947

Claim:
A method of treating a lung carcinoma comprising administration to a patient in need thereof of an effective amount of a compound of Formula Ia or Formula Ib where X is O or S; R 1 is in each instance independently selected from H, C 1 -C 6 alkyl, benzoyl, and C(O)R A ; R A is in each instance independently H, (C 1 -C 6 )alkoxy, NR B R B , or (C 1 -C 6 )alkyl, said alkyl being optionally substituted with OH, ═O, (C 1 -C 3 )alkoxy, C(O)R B , halo and NR B R B ; R B is in each instance independently H, (C 3 -C 6 )cycloalkyl, and (C 1 -C 6 )alkyl, said alkyl being optionally substituted with OH, ═O, halo, (C 1 -C 6 )alkoxy, NH(C 1 -C 3 )alkyl, N[(C 1 -C 3 )alkyl] 2 , NC(O)(C 1 -C 3 )alkyl and phenyl. and where R B , when it is attached to a N atom, is in each instance (C 1 -C 4 )alkyl, then the 2 (C 1 -C 4 )alkyl groups, taken together with the N atom to which they are attached, may be joined together to form a saturated ring, and where R B and R B together with the N to which they are attached may form a morpholinyl ring or a piperazinyl ring optionally substituted on the available N atom with (C 1 -C 6 )alkyl, said alkyl being optionally substituted with OH, ═O, NH 2 , NH(C 1 -C 3 )alkyl, N[(C 1 -C 3 )alkyl] 2 , and (C 1 -C 6 )alkoxy, and with the proviso that when R B is attached to S(O) or to S(O) 2 , it cannot be H; R 2 is selected from phenyl and naphthyl, each optionally substituted with 1, 2, or 3 substitutents each independently selected from OH, CN, NO 2 , (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, (C 3 -C 6 )cycloalkyl, halo, halo(C 1 -C 6 )alkyl, halo(C 1 -C 6 )alkoxy, C(O)R A , C(O)NR B R B , NR B R B , NH[(C 1 -C 6 )alkyl,] 0-1 S(O) 2 R B , NH[(C 1 -C 6 )alkyl] 0-1 C(O)R A , and NH[(C 1 -C 6 )alkyl] 0-1 C(O)OR B . a heterocycle selected from a six membered heterocycle, a five membered heterocycle and a fused bicyclic heterocycle, each heterocycle being optionally substituted with 1, 2 or 3 substitutents each independently selected from OH, CN, NO 2 , (C 1 -C 6 )alkyl, (C 3 -C 6 )cycloalkyl, (C 1 -C 6 )alkoxy, halo, halo(C 1 -C 6 )alkyl, halo(C 1 -C 6 )alkoxy, C(O)R A , C(O)NR B R B , NR B R B , NH[(C 1 -C 6 )alkyl,] 0-1 S(O) 2 R B , NH[(C 1 -C 6 )alkyl] 0-1 C(O)R A , and NH[(C 1 -C 6 )alkyl] 0-1 C(O)OR B , R 3 and R 4 are each independently selected from H, halo, OH, CN, (C 1 -C 3 )alkoxy, (C 1 -C 3 )alkyl, halo(C 1 -C 3 )alkoxy and halo(C 1 -C 3 )alkyl with the proviso that when X in Formula Ib is S, then R 4 cannot be (C 1 -C 3 )alkyl; B is a 5 or 6 membered cyclic moiety being optionally substituted with 1 or 2 subsituents each independently selected from ═O, OH, N oxide, halo, halo(C 1 -C 6 )alkyl, halo(C 1 -C 6 )alkoxy, (C 1 -C 6 )alkyl, (C 1 -C 3 )alkylphenyl, (C 1 -C 6 )alkoxy, C(O)R A , C(O)OR B , C(O)NR B R B , NR B R B , NH[(C 1 -C 6 )alkyl] 0-1 S(O) 2 R B , and NH[(C 1 -C 6 )alkyl] 0-1 C(O)R A ; or a pharmaceutically acceptable salt or ester thereof.